Dr. Jonathan Bones Joins PREMIER Biosoft Scientific Advisory Board to Further the Development of Glycomics Software Solutions for Biopharmaceutical Research & Development
Dr. Jonathan Bones joins PREMIER Biosoft scientific advisory board bringing in his extensive biomedical research experience to advance development of bio-pharma tools.
Palo Alto, CA, July 13, 2018 --(PR.com)-- PREMIER Biosoft today announced that Jonathan Bones, Ph.D., has joined its Scientific Advisory Board (SAB) to assist the company in its efforts to offer solutions in glycan analysis for Bio-pharmaceuticals.
In a statement, Chief Executive Officer at PREMIER Biosoft, Arun Apte said, "Dr. Bones’s remarkable contribution and experience in biomedical research and disease diagnostics will prove to be a major asset for us in developing a glycomics software solution for bio-pharmaceutical industries. We are delighted to have him on our advisory panel."
Dr. Bones obtained his BSc in Analytical Science (Chemistry) and Ph.D. in Analytical Chemistry from Dublin City University (DCU). Following completion of his doctoral studies, he took a position at the Center for Bioanalytical Science in DCU, focused on the development and application of long monolithic silica columns for high efficiency LC-MS profiling of cell culture media, a collaboration with Bristol Myers Squibb.
He joined NIBRT – The National Institute for Bioprocessing Research and Training, in 2007 based at the UCD Conway Institute of Biomolecular and Biomedical Research, representing NIBRT in the EU FP6 GLYFDIS – "Glycans in Bodily Fluids, Potential for Disease Diagnostics" Consortium. He was appointed as the GlycoAnalytical Team Leader within the Dublin-Oxford Glycobiology Laboratory.
He returned to NIBRT in 2012 and is currently exploring the use of "omics" to identify molecular manifestations in Chinese hamster Ovary (CHO) cells.
"I am delighted to join the Scientific Advisory Board alongside an impressive group of industry peers,” said Dr. Bones. “I see that PREMIER Biosoft’s current range of software products have an extensive database and robust algorithms in place for released glycan analysis. I look forward to collaborating with them to advance the development of cutting-edge informatics tools for automated rapid identification and quantitation of released N-glycans and O-glycans in biopharmaceuticals."
About PREMIER Biosoft
Founded in 1994, PREMIER Biosoft is led by computer scientists and biologists dedicated to producing cutting edge intuitive software for research in life sciences. The company's goal is to study the most recent innovations in life sciences and translate them into software products to aid research.
More information is available at: http://www.premierbiosoft.com
In a statement, Chief Executive Officer at PREMIER Biosoft, Arun Apte said, "Dr. Bones’s remarkable contribution and experience in biomedical research and disease diagnostics will prove to be a major asset for us in developing a glycomics software solution for bio-pharmaceutical industries. We are delighted to have him on our advisory panel."
Dr. Bones obtained his BSc in Analytical Science (Chemistry) and Ph.D. in Analytical Chemistry from Dublin City University (DCU). Following completion of his doctoral studies, he took a position at the Center for Bioanalytical Science in DCU, focused on the development and application of long monolithic silica columns for high efficiency LC-MS profiling of cell culture media, a collaboration with Bristol Myers Squibb.
He joined NIBRT – The National Institute for Bioprocessing Research and Training, in 2007 based at the UCD Conway Institute of Biomolecular and Biomedical Research, representing NIBRT in the EU FP6 GLYFDIS – "Glycans in Bodily Fluids, Potential for Disease Diagnostics" Consortium. He was appointed as the GlycoAnalytical Team Leader within the Dublin-Oxford Glycobiology Laboratory.
He returned to NIBRT in 2012 and is currently exploring the use of "omics" to identify molecular manifestations in Chinese hamster Ovary (CHO) cells.
"I am delighted to join the Scientific Advisory Board alongside an impressive group of industry peers,” said Dr. Bones. “I see that PREMIER Biosoft’s current range of software products have an extensive database and robust algorithms in place for released glycan analysis. I look forward to collaborating with them to advance the development of cutting-edge informatics tools for automated rapid identification and quantitation of released N-glycans and O-glycans in biopharmaceuticals."
About PREMIER Biosoft
Founded in 1994, PREMIER Biosoft is led by computer scientists and biologists dedicated to producing cutting edge intuitive software for research in life sciences. The company's goal is to study the most recent innovations in life sciences and translate them into software products to aid research.
More information is available at: http://www.premierbiosoft.com
Contact
PREMIER Bisoft
Neil Watson
650-856-2703
http://www.premierbiosoft.com/
3786 Corina Way Palo Alto, California 94303-4504 United States
Neil Watson
650-856-2703
http://www.premierbiosoft.com/
3786 Corina Way Palo Alto, California 94303-4504 United States
Contact
Categories